MD3322711T2 - Inhibitori HPK1 și metode de utilizare a acestora - Google Patents
Inhibitori HPK1 și metode de utilizare a acestoraInfo
- Publication number
- MD3322711T2 MD3322711T2 MDE20180529T MDE20180529T MD3322711T2 MD 3322711 T2 MD3322711 T2 MD 3322711T2 MD E20180529 T MDE20180529 T MD E20180529T MD E20180529 T MDE20180529 T MD E20180529T MD 3322711 T2 MD3322711 T2 MD 3322711T2
- Authority
- MD
- Moldova
- Prior art keywords
- compounds
- methods
- same
- formula
- pharmaceutically acceptable
- Prior art date
Links
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 title abstract 2
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 238000013459 approach Methods 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000003647 oxidation Effects 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Abstract
Sunt descrişi compuşii tienopiridinonici cu Formula (I) şi sărurile acceptabile farmaceutic ale acestora. În aceşti compuşi, unul dintre X1; X2 şi X3 sunt S şi celelalte două sunt fiecare independent CR, în care R şi toate celelalte variabile sunt definite aici. Se arată că compuşii inhibă activitatea kinazei HPK1 şi au activitate antitumorală in vivo. Compuşii pot fi combinaţi eficient cu purtători acceptabili farmaceutic şi, de asemenea, cu alte abordări imunomodulatoare, cum ar fi inhibarea punctului de control sau inhibitorii oxidării triptofanului. Formula (I).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562184348P | 2015-06-25 | 2015-06-25 | |
PCT/CA2016/050734 WO2016205942A1 (en) | 2015-06-25 | 2016-06-23 | Hpk1 inhibitors and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3322711T2 true MD3322711T2 (ro) | 2021-07-31 |
Family
ID=57584335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20180529T MD3322711T2 (ro) | 2015-06-25 | 2016-06-23 | Inhibitori HPK1 și metode de utilizare a acestora |
Country Status (27)
Country | Link |
---|---|
US (3) | US10501474B2 (ro) |
EP (1) | EP3322711B1 (ro) |
JP (3) | JP6898868B2 (ro) |
KR (2) | KR20240000617A (ro) |
CN (2) | CN107922431B (ro) |
AU (1) | AU2016282289B2 (ro) |
BR (2) | BR122023006150B1 (ro) |
CA (1) | CA2989684A1 (ro) |
CY (1) | CY1124489T1 (ro) |
DK (1) | DK3322711T3 (ro) |
EA (1) | EA035421B1 (ro) |
ES (1) | ES2872555T3 (ro) |
HK (1) | HK1255833A1 (ro) |
HR (1) | HRP20210895T1 (ro) |
HU (1) | HUE054159T2 (ro) |
IL (2) | IL283353B (ro) |
LT (1) | LT3322711T (ro) |
MA (1) | MA42456B1 (ro) |
MD (1) | MD3322711T2 (ro) |
MX (2) | MX2018000048A (ro) |
PL (1) | PL3322711T3 (ro) |
PT (1) | PT3322711T (ro) |
RS (1) | RS61919B1 (ro) |
SG (1) | SG10202105964RA (ro) |
SI (1) | SI3322711T1 (ro) |
TW (1) | TWI733679B (ro) |
WO (1) | WO2016205942A1 (ro) |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2989684A1 (en) * | 2015-06-25 | 2016-12-29 | University Health Network | Hpk1 inhibitors and methods of using same |
WO2018049191A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridone derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
US20180072718A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
MX2019002750A (es) | 2016-09-09 | 2019-07-04 | Incyte Corp | Derivados de pirazolopiridina como moduladores de cinasa 1 progenitora hematopoyetica (hpk1) y usos de los mismos para tratamiento de cancer. |
TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
CN110402248B (zh) | 2017-03-15 | 2023-01-06 | 豪夫迈·罗氏有限公司 | 作为hpk1抑制剂的氮杂吲哚类 |
AU2018243770A1 (en) * | 2017-03-30 | 2019-09-19 | F. Hoffmann-La Roche Ag | Isoquinolines as inhibitors of HPK1 |
WO2018183956A1 (en) * | 2017-03-30 | 2018-10-04 | Genentech, Inc. | Naphthyridines as inhibitors of hpk1 |
CA3066859A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
CA3079060A1 (en) | 2017-06-13 | 2018-12-20 | Bayer Pharma Aktiengesellschaft | Substituted pyrrolopyridine-derivatives as map4k1 modulators for the treatment of cancer diseases |
US20200246347A1 (en) | 2017-06-13 | 2020-08-06 | Bayer Pharma Aktiengesellschaft | Substituted Pyrrolopyridine-Derivatives |
WO2019016071A1 (en) | 2017-07-18 | 2019-01-24 | Bayer Pharma Aktiengesellschaft | SUBSTITUTED PYRROLOPYRIDINE DERIVATIVES |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
CN109721620B (zh) * | 2017-10-27 | 2022-05-13 | 药捷安康(南京)科技股份有限公司 | Hpk1抑制剂及其用途 |
CN111527084B (zh) * | 2017-11-06 | 2023-07-18 | 百时美施贵宝公司 | 可用作hpk1抑制剂的异呋喃酮化合物 |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
MD3755703T2 (ro) | 2018-02-20 | 2022-10-31 | Incyte Corp | Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
JP7386841B2 (ja) * | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | イソキノリン化合物及びその使用 |
JP7386842B2 (ja) | 2018-07-24 | 2023-11-27 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | ナフチリジン化合物およびその使用 |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
JP7399968B2 (ja) | 2018-09-25 | 2023-12-18 | インサイト・コーポレイション | Alk2及び/またはfgfr調節剤としてのピラゾロ[4,3-d]ピリミジン化合物 |
TW202024053A (zh) * | 2018-10-02 | 2020-07-01 | 美商建南德克公司 | 異喹啉化合物及其用途 |
JP2022504080A (ja) * | 2018-10-03 | 2022-01-13 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 8-アミノイソキノリン化合物およびその使用 |
US11612606B2 (en) | 2018-10-03 | 2023-03-28 | Genentech, Inc. | 8-aminoisoquinoline compounds and uses thereof |
EP3873903B1 (en) | 2018-10-31 | 2024-01-24 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
US11071730B2 (en) | 2018-10-31 | 2021-07-27 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US20220047603A1 (en) | 2018-12-11 | 2022-02-17 | Bayer Aktiengesellschaft | Substituted pyrrolopyridine-derivatives |
TW202039481A (zh) | 2018-12-21 | 2020-11-01 | 美商西建公司 | Ripk2之噻吩并吡啶抑制劑 |
KR20210108433A (ko) * | 2018-12-26 | 2021-09-02 | 얀센 파마슈티카 엔.브이. | 티에노피리디논 화합물 |
EP3947373A1 (en) | 2019-03-26 | 2022-02-09 | Janssen Pharmaceutica NV | Bicyclic hpk1 inhibitors |
CA3129768A1 (en) | 2019-03-26 | 2020-10-01 | Laurence Anne Mevellec | Hpk1 inhibitors |
EP3971190A4 (en) * | 2019-05-17 | 2023-06-14 | Voronoi Inc. | HETEROCYCLICALLY CONDENSED PYRIMIDIDE DERIVATE AND USE THEREOF |
US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
PE20220231A1 (es) | 2019-06-25 | 2022-02-07 | Gilead Sciences Inc | Proteinas de fusion flt3l-fc y metodos de uso |
BR112022002059A2 (pt) | 2019-08-06 | 2022-06-07 | Incyte Corp | Formas sólidas de um inibidor de hpk1 |
KR20220105631A (ko) | 2019-09-13 | 2022-07-27 | 님버스 새턴 인코포레이티드 | Hpk1 길항제 및 이의 용도 |
CN112552293A (zh) * | 2019-09-25 | 2021-03-26 | 珠海宇繁生物科技有限责任公司 | 一种protac小分子化合物及其应用 |
KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
CA3153636A1 (en) | 2019-10-31 | 2021-05-06 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US20230115523A1 (en) * | 2020-01-09 | 2023-04-13 | Sumitomo Chemical Company, Limited | Heterocyclic compound and harmful arthropod-controlling composition including same |
IL295023A (en) | 2020-02-14 | 2022-09-01 | Jounce Therapeutics Inc | Antibodies and fusion proteins that bind to ccr8 and their uses |
BR112022020814A2 (pt) * | 2020-04-13 | 2022-11-29 | Univ Health Network | Métodos para tratamento de síndrome de liberação de citocina |
CN115698009A (zh) | 2020-05-01 | 2023-02-03 | 吉利德科学公司 | 抑制cd73的2,4-二氧代嘧啶化合物 |
EP4149946A1 (en) * | 2020-05-11 | 2023-03-22 | University Health Network | Salt and crystal forms of 4-amino-5-(6-(4-methylpiperazin-1-yl)-1h-benzo[d]imidazol-2-yl)thieno[2,3-b]pyridin-6(7h)-one |
WO2021249913A1 (en) | 2020-06-09 | 2021-12-16 | Bayer Aktiengesellschaft | 2'-(quinolin-3-yl)-5',6'-dihydrospiro[azetidine-3,4'-pyrrolo[1,2-b]pyrazole]-1-carboxylate derivatives and related compounds as map4k1 (hpk1) inhibitors for the treatment of cancer |
EP4222150A1 (en) * | 2020-09-30 | 2023-08-09 | BeiGene, Ltd. | 3-[(1h-pyrazol-4-yl)oxy]pyrazin-2-amine compounds as hpk1 inhibitor and use thereof |
US20230406864A1 (en) * | 2020-11-09 | 2023-12-21 | Merck Sharp & Dohme Llc | 7-azole substituted 2-aminoquinazoline inhibitors of hpk1 |
US20240002394A1 (en) * | 2020-11-24 | 2024-01-04 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Deuterium-modified thienopyridone compound |
WO2022167627A1 (en) | 2021-02-05 | 2022-08-11 | Bayer Aktiengesellschaft | Map4k1 inhibitors |
CN117295737A (zh) | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
WO2022188823A1 (zh) * | 2021-03-10 | 2022-09-15 | 山东轩竹医药科技有限公司 | 三并环类hpk1抑制剂及其用途 |
CN116981666A (zh) * | 2021-03-26 | 2023-10-31 | 江苏恒瑞医药股份有限公司 | 稠合四环类化合物、其制备方法及其在医药上的应用 |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
WO2022226667A1 (en) * | 2021-04-30 | 2022-11-03 | Ontario Institute For Cancer Research (Oicr) | Substituted amino pyridine compounds as inhibitors of the haematopoietic progenitor kinase 1 (hpk1) |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
WO2022253252A1 (en) * | 2021-06-03 | 2022-12-08 | Silexon Biotech Co., Ltd. | Heterocyclic compounds useful as hpk1 inhibitors |
CN115433161A (zh) * | 2021-06-04 | 2022-12-06 | 轶诺(浙江)药业有限公司 | 新型hpk1抑制剂及其制备方法和应用 |
US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
CA3222595A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
US20230046340A1 (en) | 2021-06-23 | 2023-02-16 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
AU2022299051A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
TW202321239A (zh) | 2021-07-20 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 作為hpk1抑制劑用於治療癌症之經取代的吡𠯤—2—甲醯胺 |
WO2023015199A1 (en) * | 2021-08-03 | 2023-02-09 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
WO2023023942A1 (en) * | 2021-08-24 | 2023-03-02 | Biofront Ltd (Cayman) | Hpk1 inhibitors, compositions comprising hpk1 inhibitor, and methods of using the same |
WO2023057882A1 (en) * | 2021-10-05 | 2023-04-13 | Pfizer Inc. | Combinations of azalactam compounds with a pd-1 axis binding antagonist for the treatment of cancer |
AU2022364646A1 (en) * | 2021-10-15 | 2024-03-28 | Lomond Therapeutics, Inc. | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF |
US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
TW202333754A (zh) * | 2021-12-17 | 2023-09-01 | 大陸商海思科醫藥集團股份有限公司 | 並環雜環衍生物及其在醫藥上的應用 |
TW202333712A (zh) * | 2021-12-22 | 2023-09-01 | 加拿大健康網路大學 | 於急性骨髓性白血病或淋巴瘤之治療 |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230242508A1 (en) | 2021-12-22 | 2023-08-03 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023138612A1 (en) * | 2022-01-19 | 2023-07-27 | Silexon Ai Technology Co., Ltd. | Heterocyclic compounds useful as hpk1 inhibitors |
WO2023143384A1 (zh) * | 2022-01-27 | 2023-08-03 | 四川海思科制药有限公司 | 一种抑制或降解hpk1激酶的化合物及其在医药中的用途 |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
CN116462685A (zh) * | 2022-02-08 | 2023-07-21 | 和径医药科技(上海)有限公司 | 杂环化合物、包含其的药物组合物及其抗肿瘤应用 |
US20230373950A1 (en) | 2022-03-17 | 2023-11-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021615A1 (en) * | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
CA2387840A1 (en) | 1999-10-19 | 2001-04-26 | Scott R. Hambaugh | Tyrosine kinase inhibitors |
DE60140456D1 (de) * | 2000-09-01 | 2009-12-24 | Novartis Vaccines & Diagnostic | Aza heterocyclische derivate und ihre therapeutische verwendung |
AU2003249540A1 (en) | 2002-08-13 | 2004-02-25 | Warner-Lambert Company Llc | Fused bicyclic metalloproteinase inhibitors |
US7119205B2 (en) | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
WO2008143262A1 (ja) | 2007-05-21 | 2008-11-27 | Takeda Pharmaceutical Company Limited | 複素環化合物およびその用途 |
PL2262500T3 (pl) * | 2008-04-11 | 2016-09-30 | Pochodne tienopirydonowe jako aktywatory kinazy białkowej aktywowanej przez amp (ampk) | |
CA2723429C (en) | 2008-05-05 | 2016-10-11 | Daniel Cravo | Thienopyridone derivatives as amp-activated protein kinase (ampk) activators |
JP5766820B2 (ja) | 2011-02-09 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pi3キナーゼ阻害剤としての複素環化合物 |
GB201114212D0 (en) * | 2011-08-18 | 2011-10-05 | Ucb Pharma Sa | Therapeutic agents |
CA2989684A1 (en) * | 2015-06-25 | 2016-12-29 | University Health Network | Hpk1 inhibitors and methods of using same |
-
2016
- 2016-06-23 CA CA2989684A patent/CA2989684A1/en active Pending
- 2016-06-23 JP JP2017566338A patent/JP6898868B2/ja active Active
- 2016-06-23 CN CN201680048058.0A patent/CN107922431B/zh active Active
- 2016-06-23 MD MDE20180529T patent/MD3322711T2/ro unknown
- 2016-06-23 ES ES16813437T patent/ES2872555T3/es active Active
- 2016-06-23 EA EA201890059A patent/EA035421B1/ru not_active IP Right Cessation
- 2016-06-23 CN CN202110534553.5A patent/CN113214287B/zh active Active
- 2016-06-23 US US15/738,286 patent/US10501474B2/en active Active
- 2016-06-23 HU HUE16813437A patent/HUE054159T2/hu unknown
- 2016-06-23 PL PL16813437T patent/PL3322711T3/pl unknown
- 2016-06-23 BR BR122023006150-0A patent/BR122023006150B1/pt active IP Right Grant
- 2016-06-23 PT PT168134377T patent/PT3322711T/pt unknown
- 2016-06-23 WO PCT/CA2016/050734 patent/WO2016205942A1/en active Application Filing
- 2016-06-23 BR BR112017027241-5A patent/BR112017027241B1/pt active IP Right Grant
- 2016-06-23 MA MA42456A patent/MA42456B1/fr unknown
- 2016-06-23 DK DK16813437.7T patent/DK3322711T3/da active
- 2016-06-23 RS RS20210675A patent/RS61919B1/sr unknown
- 2016-06-23 KR KR1020237042987A patent/KR20240000617A/ko not_active Application Discontinuation
- 2016-06-23 AU AU2016282289A patent/AU2016282289B2/en active Active
- 2016-06-23 IL IL283353A patent/IL283353B/en unknown
- 2016-06-23 EP EP16813437.7A patent/EP3322711B1/en active Active
- 2016-06-23 MX MX2018000048A patent/MX2018000048A/es unknown
- 2016-06-23 SI SI201631189T patent/SI3322711T1/sl unknown
- 2016-06-23 KR KR1020187001327A patent/KR102614872B1/ko active IP Right Grant
- 2016-06-23 LT LTEP16813437.7T patent/LT3322711T/lt unknown
- 2016-06-23 SG SG10202105964RA patent/SG10202105964RA/en unknown
- 2016-06-24 TW TW105120043A patent/TWI733679B/zh active
-
2017
- 2017-12-11 IL IL256250A patent/IL256250B/en active IP Right Grant
-
2018
- 2018-01-08 MX MX2021011435A patent/MX2021011435A/es unknown
- 2018-11-21 HK HK18114909.1A patent/HK1255833A1/zh unknown
-
2019
- 2019-12-06 US US16/705,458 patent/US11059832B2/en active Active
-
2021
- 2021-06-07 HR HRP20210895TT patent/HRP20210895T1/hr unknown
- 2021-06-08 CY CY20211100498T patent/CY1124489T1/el unknown
- 2021-06-11 JP JP2021097834A patent/JP7241810B2/ja active Active
- 2021-07-12 US US17/372,717 patent/US20220002313A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034474A patent/JP2023071911A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3322711T2 (ro) | Inhibitori HPK1 și metode de utilizare a acestora | |
EA201990846A1 (ru) | СОЕДИНЕНИЯ БЕНЗО[b]ТИОФЕНА КАК АГОНИСТЫ STING | |
MD3377488T2 (ro) | Compuși heterociclici ca imunomodulatori | |
MD3394033T2 (ro) | Compuși heterociclici ca imunomodulatori | |
MD3472167T2 (ro) | Compuși heterociclici ca imunomodulatori | |
PH12016500055B1 (en) | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer | |
CO2017005790A2 (es) | Derivados heterocíclicos con sustituyentes que contienen azufre activos como plaguicidas | |
MD3319611T2 (ro) | Oxisteroli și metode de utilizare a acestora | |
MD3368541T2 (ro) | Compoziții și procedee de inhibare a activității arginazei | |
MD3319612T2 (ro) | Oxisteroli și metode de utilizare a acestora | |
EA201590913A1 (ru) | АЛКИЛАМИДЗАМЕЩЕННЫЕ ПИРИДИЛЬНЫЕ СОЕДИНЕНИЯ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ОТВЕТОВ, ОПОСРЕДУЕМЫХ IL-12, IL-23 И/ИЛИ IFNα | |
GEP20186933B (en) | Substituted dihydroisoquinoline compounds | |
MX349827B (es) | Compuestos que contienen nitrogeno y su uso. | |
MX2015010125A (es) | Derivados de piridazinona-amidas. | |
MX2016009248A (es) | Compuestos que contienen nitrogeno y su uso como agentes antibacterianos. | |
MX2016002975A (es) | Compuestos antimicrobianos y métodos de fabricación y utilización de los mismos. | |
MX2014014832A (es) | Pirrolopirimidona y pirrolopiridona, inhibidores de tanquirasa. | |
EA201591362A1 (ru) | Соединения и способы лечения бактериальных инфекций | |
EA201692550A1 (ru) | Соединения, содержащие систему 1,1',2,5'-тетрагидроспиро[индол-3,2'-пиррол]-2,5'-диона в качестве ингибиторов белок-белкового взаимодействия p53-mdm2 | |
EA201890632A1 (ru) | Хиральные фосфорамидимидаты и их производные | |
MX358429B (es) | Nuevos derivados de isocromano e isotiocromano agonistas del adrenoreceptor alfa2a, especialmente agonistas del adrenoreceptor alfa2a para usarse como sedantes o analgesicos. | |
MD3562822T2 (ro) | Inhibitori de poli-ADP riboză polimerază (PARP) | |
MD3355890T2 (ro) | Inhibitori de kalikreină plasmatică umană | |
EA201791099A1 (ru) | Хинолин карбоксамиды для применения в лечении лейкоза | |
MX2016004509A (es) | Compuestos que contienen nitrogeno y su uso. |